오리엔트바이오, 당해 영업손실 41억원…적자 확대

OrientBio reported a 34.3% increase in operating losses while maintaining modest 1.2% revenue growth, signaling deteriorating core business profitability. The surge in operating losses, driven primarily by increased inventory valuation provisions, reveals challenges in inventory management and demand forecasting within the competitive biotech sector.